Sonnet BioTherapeutics Stock (NASDAQ: SONN) stock price, news, charts, stock research, profile.
Open | $1.700 |
Close | $1.780 |
Volume / Avg. | 18.325K / 101.196K |
Day Range | 1.660 - 1.840 |
52 Wk Range | 1.080 - 26.400 |
Market Cap | $5.187M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 50 |
Short Interest | 15.16% |
Days to Cover | 5.79 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Sonnet BioTherapeutics (NASDAQ: SONN) through any online brokerage.
Other companies in Sonnet BioTherapeutics’s space includes: Alzamend Neuro (NASDAQ:ALZN), Tharimmune (NASDAQ:THAR), Synaptogenix (NASDAQ:SNPX), NexImmune (NASDAQ:NEXI) and Genprex (NASDAQ:GNPX).
The latest price target for Sonnet BioTherapeutics (NASDAQ: SONN) was reported by Chardan Capital on Thursday, February 15, 2024. The analyst firm set a price target for 30.00 expecting SONN to rise to within 12 months (a possible 1675.15% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Sonnet BioTherapeutics (NASDAQ: SONN) is $1.69 last updated April 22, 2024 at 4:01 PM EDT.
There are no upcoming dividends for Sonnet BioTherapeutics.
Sonnet BioTherapeutics’s Q2 earnings are confirmed for Wednesday, May 8, 2024.
There is no upcoming split for Sonnet BioTherapeutics.
Sonnet BioTherapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.